Donor Age ≥30 Years as an Independent Predictor of Inferior Outcomes After Haploidentical Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Study Conducted on Behalf of GETH-TC

Donor Age ≥30 Years as an Independent Predictor of Inferior Outcomes After Haploidentical Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Study Conducted on Behalf of GETH-TC | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Donor Age ≥30 Years as an Independent Predictor of Inferior Outcomes After Haploidentical Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Study Conducted on Behalf of GETH-TC Daniel Munárriz, Estefanía Pérez, Carlos Martín-Rodriguez, Marta Luque, and 19 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7169285/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract This study evaluated the impact of donor age on clinical outcomes in 274 patients with acute myeloid leukemia (AML) haplo-HCT using PTCY-based prophylaxis. Median patient age was 53 years, with 42.6% classified as high-risk AML. The median donor age of 38 years; 31% were under 30. An optimal donor age cut-off of 30 years was identified through ROC analysis. Patients receiving grafts from younger donors (<30 years) showed lower rates of aGVHD grade II–IV (3.0% vs. 19.9%, p < 0.001) and grade III–IV (1.5% vs. 10.2%, p = 0.034), with no differences in cGVHD or relapse rates. Overall survival (OS) was higher in the younger donor group (2-year: 80.6% vs. 64.3%, p = 0.011), along by lower non-relapse mortality (NRM) (2-year: 11.1% vs. 23.2%, p = 0.031). Multivariate analysis confirmed donor age ≥30 years as an independent adverse factor for OS (HR: 1.88, p = 0.019) and NRM (HR: 2.06, p = 0.049), along with older recipient age, higher HCT-CI score, and high-risk AML. These findings suggest that younger donor age contributes to improved survival, primarily through reduced NRM and aGVHD, supporting prioritization of younger donors when multiple haploidentical options are available to optimize transplant outcomes. Biological sciences/Cancer/Haematological cancer/Leukaemia/Acute myeloid leukaemia Health sciences/Diseases/Cancer/Cancer therapy Full Text Additional Declarations The authors have declared there is NO conflict of interest to disclose. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7169285","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":489487945,"identity":"5d38528f-011b-4b0f-81c4-720fbea8d29e","order_by":0,"name":"Daniel Munárriz","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA6ElEQVRIiWNgGAWjYDCCA0D0AMRg7/8Ionn4iNKSAGLwHDA2AFFsxGhhAGuRSDCTANEEtfAdP3vwQELFPXn+GQlplV9z7GTYGJgfPrqBR4vkmbyEAwlnig1nnHlw7LbstmSgw9iMjXPwaDE4kGNwILEtIYHheGLbbcltzEAtPGzSeLWcfwPRIn8gma1Ycls9EVpuQG0xOJHGxvhx22HCWiRvAG1JOJNguPHMGWZpxm3HediYCfiF73yO8YcPFQnycsd7GD/+3FZtz8/e/PAxPi0ogJkHTBKrHAQYf5CiehSMglEwCkYMAABz10536+QJogAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0009-0005-4977-8782","institution":"Hospital Clinic de Barcelona","correspondingAuthor":true,"prefix":"","firstName":"Daniel","middleName":"","lastName":"Munárriz","suffix":""},{"id":489487947,"identity":"0aa5f6be-eeaf-422f-9c80-f8949552ddee","order_by":1,"name":"Estefanía Pérez","email":"","orcid":"","institution":"Complejo Asistencial Universitario de Salamanca-IBSAL, Centro de Investigación del Cáncer-IBMCC, Spain","correspondingAuthor":false,"prefix":"","firstName":"Estefanía","middleName":"","lastName":"Pérez","suffix":""},{"id":489487949,"identity":"7df4094e-2b75-45c4-a12b-768cce872cf5","order_by":2,"name":"Carlos Martín-Rodriguez","email":"","orcid":"https://orcid.org/0000-0002-9621-2133","institution":"Hospital Universitario de Salamanca-IBSAL","correspondingAuthor":false,"prefix":"","firstName":"Carlos","middleName":"","lastName":"Martín-Rodriguez","suffix":""},{"id":489487950,"identity":"4d7c8a67-aa9d-4e64-aa41-7d3769f64b65","order_by":3,"name":"Marta Luque","email":"","orcid":"","institution":"Hospital Regional Universitario de Málaga","correspondingAuthor":false,"prefix":"","firstName":"Marta","middleName":"","lastName":"Luque","suffix":""},{"id":489487952,"identity":"d6ed5e01-df79-4387-b26a-355346138cfa","order_by":4,"name":"Albert Esquirol","email":"","orcid":"https://orcid.org/0000-0002-6062-5980","institution":"Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau and Jose Carreras Leukemia Research Institutes. Universitat Autonoma of Barcelona","correspondingAuthor":false,"prefix":"","firstName":"Albert","middleName":"","lastName":"Esquirol","suffix":""},{"id":489487953,"identity":"1248908e-b283-496f-a4ce-fae8b7c6f19b","order_by":5,"name":"Carmen Martín","email":"","orcid":"","institution":"Reina Sofia University Hospital","correspondingAuthor":false,"prefix":"","firstName":"Carmen","middleName":"","lastName":"Martín","suffix":""},{"id":489487955,"identity":"f9a94a5c-e554-4ce4-834c-c0e26f9fa6e3","order_by":6,"name":"Clara Aparicio","email":"","orcid":"","institution":"Hospital Reina Sofía de Córdoba","correspondingAuthor":false,"prefix":"","firstName":"Clara","middleName":"","lastName":"Aparicio","suffix":""},{"id":489487956,"identity":"4d6f3f72-7643-4121-b9cd-fe38c2a61179","order_by":7,"name":"Felipe Pena-Munoz","email":"","orcid":"https://orcid.org/0000-0003-2667-716X","institution":"Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona","correspondingAuthor":false,"prefix":"","firstName":"Felipe","middleName":"","lastName":"Pena-Munoz","suffix":""},{"id":489487958,"identity":"e77d4eec-c578-4ec8-897d-0b88d43838a1","order_by":8,"name":"Inmaculada Heras","email":"","orcid":"","institution":"University Hospital Morales Meseguer","correspondingAuthor":false,"prefix":"","firstName":"Inmaculada","middleName":"","lastName":"Heras","suffix":""},{"id":489487959,"identity":"25cb7d03-b32f-4df5-839a-ac23b2e4dba1","order_by":9,"name":"Itziar Oiartzabal Ormategi","email":"","orcid":"","institution":"Hospital Universitario Donostia","correspondingAuthor":false,"prefix":"","firstName":"Itziar","middleName":"Oiartzabal","lastName":"Ormategi","suffix":""},{"id":489487960,"identity":"e3416b68-b2b4-4fe5-81da-8bd08d34a593","order_by":10,"name":"Adolfo Sáez-Marín","email":"","orcid":"https://orcid.org/0000-0002-7372-5219","institution":"Hospital Universitario 12 de Octubre, Madrid","correspondingAuthor":false,"prefix":"","firstName":"Adolfo","middleName":"","lastName":"Sáez-Marín","suffix":""},{"id":489487961,"identity":"5bbedf0a-2114-4789-bbc8-201e94eff571","order_by":11,"name":"Sara Fernandez-Luis","email":"","orcid":"https://orcid.org/0000-0001-9630-5893","institution":"Hospital Universitario Marqués de Valdecilla","correspondingAuthor":false,"prefix":"","firstName":"Sara","middleName":"","lastName":"Fernandez-Luis","suffix":""},{"id":489487962,"identity":"849ebe07-af44-4a8f-904b-7edd85e4e5d7","order_by":12,"name":"Juan Domínguez-García","email":"","orcid":"https://orcid.org/0000-0001-6210-1294","institution":"Hospital Universitario Marqués de Valdecilla. IDIVAL.","correspondingAuthor":false,"prefix":"","firstName":"Juan","middleName":"","lastName":"Domínguez-García","suffix":""},{"id":489487963,"identity":"05a9e4cb-d01f-4d05-85bd-f4e6756a5c1a","order_by":13,"name":"Sara Villar","email":"","orcid":"https://orcid.org/0000-0002-4761-6692","institution":"Clínica Universidad de Navarra","correspondingAuthor":false,"prefix":"","firstName":"Sara","middleName":"","lastName":"Villar","suffix":""},{"id":489487964,"identity":"c5917af4-38bc-4e59-aa91-6afdac937650","order_by":14,"name":"Jose Luis Lopez Lorenzo","email":"","orcid":"https://orcid.org/0000-0003-1502-3902","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Jose","middleName":"Luis Lopez","lastName":"Lorenzo","suffix":""},{"id":489487965,"identity":"7e398475-88df-493b-978f-71d74646926f","order_by":15,"name":"Cynthia Acosta Fleitas","email":"","orcid":"","institution":"Hospital Universitario de Gran Canaria Doctor Negrín","correspondingAuthor":false,"prefix":"","firstName":"Cynthia","middleName":"Acosta","lastName":"Fleitas","suffix":""},{"id":489487966,"identity":"dd6a668a-c076-42ca-b91e-6be7fe7a5cc5","order_by":16,"name":"Ana Pilar Gonzalez-Rodriguez","email":"","orcid":"","institution":"Hospital Universitario Central de Asturias","correspondingAuthor":false,"prefix":"","firstName":"Ana","middleName":"Pilar","lastName":"Gonzalez-Rodriguez","suffix":""},{"id":489487967,"identity":"86bf0838-ecf7-443f-b905-0d410ec44969","order_by":17,"name":"Lucia Garcia-Mañó","email":"","orcid":"","institution":"Hospital Universitario Son Espases, Islas Baleares, Spain","correspondingAuthor":false,"prefix":"","firstName":"Lucia","middleName":"","lastName":"Garcia-Mañó","suffix":""},{"id":489487968,"identity":"711aaace-ab88-49cb-8609-c8e337d74c20","order_by":18,"name":"Tamara Torrado","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Tamara","middleName":"","lastName":"Torrado","suffix":""},{"id":489487969,"identity":"f0cd50f0-0b4d-498b-86d8-de8bac8643c4","order_by":19,"name":"Silvia Filaferro","email":"","orcid":"","institution":"Grupo Español de Trasplantes Hematopoyéticos y Terapia Celular (GETH-TC)","correspondingAuthor":false,"prefix":"","firstName":"Silvia","middleName":"","lastName":"Filaferro","suffix":""},{"id":489487970,"identity":"538eaaad-899e-4be3-b579-630a94e02a76","order_by":20,"name":"Pascual Balsalobre","email":"","orcid":"","institution":"Grupo Español de Trasplantes Hematopoyéticos y Terapia Celular (GETH-TC)","correspondingAuthor":false,"prefix":"","firstName":"Pascual","middleName":"","lastName":"Balsalobre","suffix":""},{"id":489487971,"identity":"0771b0eb-f8d2-4db1-9a75-2cb7d669eefc","order_by":21,"name":"María Pascual","email":"","orcid":"","institution":"SAS","correspondingAuthor":false,"prefix":"","firstName":"María","middleName":"","lastName":"Pascual","suffix":""},{"id":489487972,"identity":"ebc55779-50ff-4429-bd27-9a9810b2a559","order_by":22,"name":"Maria Queralt Salas","email":"","orcid":"https://orcid.org/0000-0003-4567-3682","institution":"Hospital Clinic de Barcelona","correspondingAuthor":false,"prefix":"","firstName":"Maria","middleName":"Queralt","lastName":"Salas","suffix":""}],"badges":[],"createdAt":"2025-07-20 11:10:13","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7169285/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7169285/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":90602053,"identity":"c47bca57-6567-4a02-9623-65038e86248f","added_by":"auto","created_at":"2025-09-04 14:46:07","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":785226,"visible":true,"origin":"","legend":"Article File","description":"","filename":"ManuscriptDonorAgehaploHCT.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7169285/v1_covered_de4bfb19-8d16-40bc-aba3-42201e0c6011.pdf"}],"financialInterests":"The authors have declared there is \u003cb\u003eNO\u003c/b\u003e conflict of interest to disclose.","formattedTitle":"Donor Age ≥30 Years as an Independent Predictor of Inferior Outcomes After Haploidentical Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Study Conducted on Behalf of GETH-TC","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-7169285/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7169285/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"This study evaluated the impact of donor age on clinical outcomes in 274 patients with acute myeloid leukemia (AML) haplo-HCT using PTCY-based prophylaxis. Median patient age was 53 years, with 42.6% classified as high-risk AML. The median donor age of 38 years; 31% were under 30. An optimal donor age cut-off of 30 years was identified through ROC analysis. Patients receiving grafts from younger donors (\u003c30 years) showed lower rates of aGVHD grade II–IV (3.0% vs. 19.9%, p \u003c 0.001) and grade III–IV (1.5% vs. 10.2%, p = 0.034), with no differences in cGVHD or relapse rates. Overall survival (OS) was higher in the younger donor group (2-year: 80.6% vs. 64.3%, p = 0.011), along by lower non-relapse mortality (NRM) (2-year: 11.1% vs. 23.2%, p = 0.031). Multivariate analysis confirmed donor age ≥30 years as an independent adverse factor for OS (HR: 1.88, p = 0.019) and NRM (HR: 2.06, p = 0.049), along with older recipient age, higher HCT-CI score, and high-risk AML. These findings suggest that younger donor age contributes to improved survival, primarily through reduced NRM and aGVHD, supporting prioritization of younger donors when multiple haploidentical options are available to optimize transplant outcomes.","manuscriptTitle":"Donor Age ≥30 Years as an Independent Predictor of Inferior Outcomes After Haploidentical Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Study Conducted on Behalf of GETH-TC","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-07-25 08:18:07","doi":"10.21203/rs.3.rs-7169285/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"4df1a009-40ba-4cd8-8b29-4597ee9a013b","owner":[],"postedDate":"July 25th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":51964907,"name":"Biological sciences/Cancer/Haematological cancer/Leukaemia/Acute myeloid leukaemia"},{"id":51964908,"name":"Health sciences/Diseases/Cancer/Cancer therapy"}],"tags":[],"updatedAt":"2025-09-04T14:37:59+00:00","versionOfRecord":[],"versionCreatedAt":"2025-07-25 08:18:07","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7169285","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7169285","identity":"rs-7169285","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}